Charles River Laboratories
CRL
Market cap $7.34B

149.45 USD

-2.44

1.61%

At close Jun 13, 4:00 PM EDT

After hours

149.45

+0.00

0.00%

1 day

-1.61%

5 days

1.97%

1 month

3.77%

3 months

-10.47%

6 months

-21.53%

Year to date

-18.17%

1 year

-29.65%

5 years

-16.85%

10 years

106.42%

About: Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Employees: 20,100

Healthcare Diagnostics & Research

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.03% less ownership

Funds ownership: 103.58% [Q4 2024] → 103.55% (-0.03%) [Q1 2025]

12% less funds holding

Funds holding: 628 [Q4 2024] → 552 (-76) [Q1 2025]

16% less call options, than puts

Call options by funds: $106M | Put options by funds: $125M

20% less capital invested

Capital invested by funds: $10B [Q4 2024] → $7.96B (-$2.04B) [Q1 2025]

22% less repeat investments, than reductions

Existing positions increased: 186 | Existing positions reduced: 237

47% less first-time investments, than exits

New positions opened: 70 | Existing positions closed: 133

50% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$140

6%

downside

Avg. target

$160

7%

upside

High target

$182

22%

upside

5 analyst ratings

1 positive

20%

4 neutral

80%

0 negative

0%

Redburn Atlantic Jamie Clark	22%upside $182	Buy Upgraded	23 May 2025
Barclays Luke Sergott	4%upside $155	Equal-Weight Maintained	8 May 2025
Baird Eric Coldwell	6%downside $140	Neutral Maintained	8 May 2025
Mizuho Ann Hynes	4%upside $155	Neutral Maintained	9 Apr 2025
Goldman Sachs Matthew Sykes	14%upside $170	Neutral Downgraded	21 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CRL published over the past 30 days

Zacks Investment Research

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

Zacks Investment Research

Charles River Stock May Gain From Extended CHDI Research Deal on HD

CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.

Charles River Stock May Gain From Extended CHDI Research Deal on HD

Charles River Laboratories to Present at William Blair and Jefferies Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at William Blair and Jefferies Conferences.

Charles River Laboratories to Present at William Blair and Jefferies Conferences

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and CHDI announce an extension of their partnership, having worked together since 2005 to expedite therapies for Huntington's disease.

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

Zacks Investment Research

Should You Continue to Hold Charles River Stock in Your Portfolio?

CRL stays on investors' radars due to the strength of partnerships and segmental prospects.

Should You Continue to Hold Charles River Stock in Your Portfolio?

Zacks Investment Research

Understanding Charles River (CRL) Reliance on International Revenue

Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Understanding Charles River (CRL) Reliance on International Revenue

Charles River Laboratories to Present at Bank of America Health Care Conference

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Bank of America Health Care Conference.

Charles River Laboratories to Present at Bank of America Health Care Conference

Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

The firm has three possible paths toward value creation at the drug development company.

Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript

Charles River Laboratories International, Inc. (NYSE:CRL ) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Max Smock - William Blair Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Ann Hynes - Mizuho Securities Dave Windley - Jefferies Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Kyle Crews - UBS Patrick Donnelly - Citi Casey Woodring - JPMorgan Charles Rhyee - TD Cowen Tejas Savant - Morgan Stanley Rob Cottrell - Cleveland Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories First Quarter 2025 Earnings Conference Call. This call is being recorded.

Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™